全球再生医学胶原蛋白和明胶市场规模（按来源、应用、地区、范围和预测）

再生医学用胶原蛋白及明胶的市场规模及预测

再生医学的胶原蛋白和明胶市场预计在 2024 年达到 9.5428 亿美元，在 2031 年达到 16.2613 亿美元，2024 年至 2031 年的复合年增长率为 7.6%。胶原蛋白是人体内最常见的蛋白质，存在于皮肤、关节和骨骼等结缔组织中，提供结构和稳定性。明胶是部分水解且三螺旋结构变性的胶原蛋白。胶原蛋白和明胶因其生物相容性、细胞识别位点和可调节的生物降解性而被应用于再生医学，从而推动了组织工程、细胞治疗和增强药物传递方面的突破性进展。

此外，胶原支架可促进细胞发育和沈积，但由于明胶的独特性质，可以对其进行改性以改善其生物和功能特性，从而支持组织再生。

再生医学用胶原蛋白和明胶的全球市场动态

主要市场驱动因子

慢性病和伤害盛行率不断上升：

需要组织修復和再生的慢性疾病和损伤的日益流行是再生医学市场胶原蛋白和明胶的主要驱动力。根据世界卫生组织（WHO）的数据，慢性病占全球所有死亡人数的71%，即每年4,100万人。根据美国疾病管制与预防中心(CDC) 的数据，大约四分之一(26%) 的美国成年人患有某种类型的残疾，其中许多人可以从使用胶原蛋白和明胶的再生医学治疗中受益。

老年人口不断增加：

全球人口老化正在推动对再生医学用胶原蛋白和明胶解决方案的需求。根据联合国《2019年世界人口前景》报告，到2050年，每六人中就有一人年龄超过65岁（16%），高于每十一个人中就有一人（9%）。这种人口结构变化导致与年龄相关的疾病（如骨关节炎）的发生率上升，根据美国疾病管制与预防中心统计，仅在美国就有约 3,250 万人患有骨关节炎。胶原蛋白和明胶类药物在解决这些与年龄相关的问题的潜力正在推动市场扩张。

组织工程与再生医学研究的进展：

组织工程和再生医学的持续研究和开发正在推动胶原蛋白和明胶市场向前发展。美国国立卫生研究院（NIH）报告称，2020财政年度将在再生医学研究方面投资约25亿美元。此外，再生医学联盟报告称，截至 2020 年底，全球共有 1,220 项再生医学和先进疗法临床试验正在进行，其中许多涉及基于胶原蛋白和明胶的技术。

主要问题

替代生物材料的可用性：

壳聚醣、海藻酸盐和透明质酸等替代生物材料的出现对胶原蛋白和明胶市场构成了重大课题。这些替代材料具有类似甚至更好的癒合和再生特性，推动了製造商和医疗保健专业人员的选择转变。随着这些替代品越来越受欢迎，它们限制了胶原蛋白和明胶基产品在再生应用领域的成长潜力，严重影响了市场动态。

批次差异与品质控制问题：

胶原蛋白和明胶产品批次间存在差异，产生一致性和品质问题。这种不可预测性使製造过程变得复杂，并降低了这些生物材料在治疗环境中的可靠性。此外，净化和品质控制的困难阻碍了研究人员和临床医生充分采用这些产品，限制了它们在再生医学中的广泛应用。

主要趋势：

对植物性、永续来源的需求不断增加：

出于道德和环境方面的考虑，消费者越来越青睐植物性、可持续的胶原蛋白和明胶来源。这就导致了从海藻、米蛋白和豌豆蛋白中提取的新替代品的出现。各公司正在投资研究，开发更有效率、更环保的生产工艺，以满足再生医学应用对植物替代品日益增长的需求。

在高阶伤口护理和组织工程中的应用日益广泛：

胶原蛋白和明胶由于其高度的生物相容性、生物降解性和促进细胞发育和组织再生的能力，越来越多地被用于先进的伤口护理和组织工程。该公司投资研发，开发用于伤口癒合、骨再生和器官替代的创新胶原蛋白和明胶解决方案。慢性伤口、糖尿病和癌症的发生率不断上升，推动了对这些先进再生医学解决方案的需求。

目录

第 1 章。

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 主要来源
• 资料来源列表

第 4 章。

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析
• 监理框架

第 5 章。

• 胶原蛋白原料
  • 牛
  • 猪
  • 海洋
• 明胶原料
  • 牛
  • 猪
  • 其他

6. 全球再生医学胶原蛋白及明胶市场（依应用）

• 胶原蛋白
  • 骨科
  • 伤口护理
  • 循环系统
  • 其他
• 明胶
  • 伤口护理
  • 骨科
  • 循环系统
  • 其他

7. 全球再生医学胶原蛋白和明胶市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

8. 全球再生医学胶原蛋白与明胶市场：竞争格局

• 概述
• 公司市占率
• 供应商概况
• 主要发展策略

第九章 公司简介

• Integra Lifesciences Holdings Corporation
• Collagen Matrix, Inc.
• Collagen Solutions PLC
• Royal DSM
• VorniaBiomaterials Ltd.
• Symatese
• Nucollagen LLC.
• Gelita AG
• Nitta Gelatin Inc.
• PB Gelatin

第 10 章附录

• 相关研究

Collagen and Gelatin Market for Regenerative Medicine Market Size and Forecast

Collagen and Gelatin Market for Regenerative Medicine Market size was valued at USD 954.28 Million in 2024 and is projected to reach USD 1626.13 Million by 2031, growing at a CAGR of 7.6% from 2024 to 2031. Collagen is the body's most prevalent protein, found in connective tissues such as skin, joints, and bones, where it provides structure and stability. Gelatin is a deteriorated form of collagen that results from partial hydrolysis, which denatures the triple helical structure. Collagen and gelatin are employed in regenerative medicine due to their biocompatibility, cell recognition sites, and tunable biodegradability, which enable breakthroughs in tissue engineering, cellular treatment, and enhanced drug administration.

Furthermore, collagen scaffolds promote cell development and deposition, but gelatin's unique features allow it to be changed to improve its biological and functional qualities, opening up new avenues for biomaterials that can support tissue regeneration.

Global Collagen and Gelatin Market for Regenerative Medicine Market Dynamics

The key market dynamics that are shaping the collagen and gelatin market for regenerative medicine market include:

Key Market Drivers

Increasing Prevalence of Chronic Diseases and Injuries:

The increasing prevalence of chronic diseases and injuries necessitating tissue repair and regeneration is a major driver of the collagen and gelatin market for regenerative medicine. According to the World Health Organization (WHO), chronic diseases account for 71% of all deaths worldwide, or 41 million people per year. According to the Centers for Disease Control and Prevention (CDC), approximately one in every four adults (26%) in the United States suffers from some form of impairment, many of which could benefit from regenerative medicine treatments utilizing collagen and gelatin.

Growing Aging Population:

The worldwide aging population is boosting demand for regenerative medicine solutions based on collagen and gelatin. According to the United Nations World Population Prospects 2019 report, by 2050, one in every six individuals will be beyond the age of 65 (16%), up from one in every eleven (9%). This demographic change is driving up the prevalence of age-related illnesses like osteoarthritis, which affects an estimated 32.5 million individuals in the United States alone, according to the CDC. The potential for collagen and gelatin-based medicines to address these age-related problems is driving market expansion.

Advancements in Tissue Engineering and Regenerative Medicine Research:

Continuous research and development in tissue engineering and regenerative medicine are driving the collagen and gelatin market forward. The National Institutes of Health (NIH) reports that it invested around USD 2.5 Billion in regenerative medicine research in fiscal year 2020. Also, the Alliance for Regenerative Medicine reports that 1,220 clinical trials in regenerative medicine and advanced therapies will be underway worldwide by the end of 2020, with many of them involving collagen and gelatin-based techniques.

Key Challenges:

Availability of Alternative Biomaterials:

The emergence of replacement biomaterials such as chitosan, alginate, and hyaluronic acid presents a substantial challenge to the collagen and gelatin market. These alternatives offer equivalent or superior healing and regeneration qualities, prompting a shift in choice among manufacturers and healthcare professionals. As these replacements acquire popularity, they limit the growth potential of collagen and gelatin-based products in regenerative applications, severely affecting market dynamics.

Batch Variability and Quality Control Issues:

Collagen and gelatin products have batch-to-batch variability, raising issues about uniformity and quality. This unpredictability complicates the manufacturing process and reduces the dependability of these biomaterials in therapeutic settings. Furthermore, difficulties with purification and quality control prevent researchers and clinicians from completely adopting these products, restricting their widespread use in regenerative medicine.

Key Trends:

Growing Demand for Plant-Based and Sustainable Sources:

Consumers are increasingly preferring plant-based and sustainable sources of collagen and gelatin, driven by ethical and environmental concerns. This has resulted in the creation of novel alternatives derived from seaweed, rice protein, and pea protein. Companies are investing in research to develop more efficient and environmentally friendly production processes to address the growing demand for plant-based alternatives in regenerative medical applications.

Increasing Use in Advanced Wound Care and Tissue Engineering:

Collagen and gelatin are increasingly being used in advanced wound care and tissue engineering due to their high biocompatibility, biodegradability, and ability to encourage cell development and tissue regeneration. Companies are investing in R&D to develop innovative collagen and gelatin-based solutions for wound healing, bone regeneration, and organ replacement. The increasing prevalence of chronic wounds, diabetes, and cancer is fueling the demand for these advanced regenerative medicine solutions.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Collagen and Gelatin Market for Regenerative Medicine Market Regional Analysis

Here is a more detailed regional analysis of the collagen and gelatin market for regenerative medicine market:

North America:

According to Verified Market Research, North America is estimated to dominate the collagen and gelatin market for regenerative medicine market over the forecast period. North America, particularly the United States, has a high prevalence of chronic diseases and injuries that could benefit from regenerative medicine treatments based on collagen and gelatin. According to the Centers for Disease Control and Prevention (CDC), six out of every ten persons in the United States have a chronic disease, with four out of ten having two or more. According to the CDC, approximately 54.4 million US individuals (or around 23%) have doctor-diagnosed arthritis, a condition for which collagen-based medicines show promise. The region's high disease load increases the demand for innovative regenerative medicine treatments.

Furthermore, North America is at the forefront of regenerative medicine research and development, which is driving the collagen and gelatin market. The California Institute for Regenerative Medicine (CIRM), the United States' largest state-funded stem cell agency, has committed more than USD 3 Billion in regenerative medicine research since its creation. In addition, the National Institutes of Health (NIH) reported funding for regenerative medicine research of around USD 2.5 Billion in fiscal year 2020. This large investment supports regional innovation and market growth.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth within the market during the forecast period. The Asia Pacific region's aging population is rapidly growing, resulting in increased demand for regenerative medicine solutions. According to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), the region's elder population (aged 65 and more) is predicted to more than double from 535 million in 2015 to around 1.3 billion by 2050. In East and North-East Asia, the population aged 65 and up is expected to grow from 260 million in 2020 to 573 million by 2050. This demographic shift increases the demand for collagen and gelatin-based regenerative medicines to address age-related health concerns.

Furthermore, the Asia Pacific region is experiencing an increase in chronic diseases, resulting in a significant market for regenerative medicine. According to the World Health Organization (WHO), non-communicable diseases (NCDs) account for 71% of all deaths worldwide, with a disproportionate impact on low- and middle-income nations, the majority of which are in Asia. According to the International Diabetes Federation (IDF), the number of adults with diabetes in Southeast Asia is anticipated to grow from 88 million in 2019 to 153 million by 2045. This increased illness load is encouraging the use of advanced regeneration treatments such as collagen and gelatin.

Europe:

Europe region is estimated to exhibit substantial growth within the market during the forecast period. Europe has one of the world's oldest populations, which fuels demand for regenerative medicine treatments. According to Eurostat, the proportion of adults 65 and older in the EU-27 is expected to rise from 20.3% in 2019 to 29.4% by 2050. This demographic transition coincides with an increase in age-related ailments. For example, the European League Against Rheumatism (EULAR) estimates that over 120 million people in the EU suffer from rheumatic and musculoskeletal illnesses (RMDs), many of which could benefit from collagen and gelatin-based regenerative therapies. The aging population and accompanying health challenges are driving the regenerative medicine market in Europe.

Furthermore, Europe is witnessing an increasing burden of chronic diseases, providing a sizable market for regenerative medicine treatments. Chronic diseases, according to the World Health Organization (WHO), account for 86% of fatalities and 77% of disease burden in Europe. The European Heart Network states that cardiovascular disease kills 3.9 million people in Europe each year, accounting for 45% of all deaths. Many of these chronic illnesses benefit from collagen and gelatin-based regenerative therapies, resulting in market expansion.

Collagen and Gelatin Market for Regenerative Medicine Market: Segmentation Analysis

The Global Collagen and Gelatin Market for Regenerative Medicine Market is segmented based on Source, Application, and Geography.

Collagen and Gelatin Market for Regenerative Medicine Market, By Source

• Bovine
• Porcine
• Marine
• Others

Based on Source, the Collagen and Gelatin Market for Regenerative Medicine Market is segmented into Bovine, Porcine, Marine, and Others. The bovine segment is estimated to dominate the collagen and gelatin market for regenerative medicine market due to the extensive use of bovine-derived collagen and gelatin, which are highly biocompatible and biodegradable. Because of the huge scale of cow ranching, bovine supplies are frequently less expensive, making them a preferred alternative for a variety of regenerative medicine applications such as wound care and orthopedic operations, resulting in market leadership.

Collagen and Gelatin Market for Regenerative Medicine Market, By Application

• Wound Care
• Orthopedic
• Cardiovascular
• Others

Based on Application, the Collagen and Gelatin Market for Regenerative Medicine Market is segmented into Wound Care, Orthopedic, Cardiovascular, and Others. The orthopedic segment is estimated to dominate the collagen and gelatin market for regenerative medicine market due to the increasing use of collagen and gelatin-based biomaterials in orthopedic procedures such as joint replacements and bone restoration. The rising prevalence of orthopedic disorders, combined with advances in surgical procedures and product improvements, has greatly increased demand for these materials, making orthopedics the market's largest application segment.

Collagen and Gelatin Market for Regenerative Medicine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Geography, the Collagen and Gelatin market for regenerative medicine market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is estimated to dominate the market during the forecasted period due to the high prevalence of chronic diseases, a well-developed healthcare infrastructure, and the existence of major market participants. The region's excellent research capabilities and major investments in regenerative medicine strengthen its position. Furthermore, the growing use of collagen-based products in a variety of medical applications, such as wound care and orthopedic procedures, helps North America maintain its market leadership.

Key Players

• The "Collagen and Gelatin Market for Regenerative Medicine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Integra Lifesciences Holdings Corporation, Collagen Matrix Inc., Collagen Solutions PLC, Royal DSM, VorniaBiomaterials Ltd., Symatese, Nucollagen LLC., Gelita AG, Nitta Gelatin, Inc., and PB Gelatin.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Collagen and Gelatin Market for Regenerative Medicine Market Recent Developments
• In January 2023, TELA Bio, Inc. developed the NIVIS Fibrillar Collagen Pack, an absorbent matrix composed of Type I and Type III bovine collagen. This product is intended to address moderately to heavily oozing wounds and minimal bleeding, and it represents a substantial contribution to the company's regenerative medicine portfolio. The launch demonstrates TELA Bio's dedication to providing improved wound care products.
• In October 2022, Collagen Matrix announced the acquisition of Polyganics B.V., to increase its range of bioresorbable products and technological platforms for bone and tissue restoration. This acquisition is expected to strengthen Collagen Matrix's regenerative medicine capabilities, allowing for the development of novel solutions to address the growing need for surgical applications.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL COLLAGEN AND GELATIN MARKET FOR REGENERATIVE MEDICINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL COLLAGEN AND GELATIN MARKET FOR REGENERATIVE MEDICINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis
• 4.5 Regulatory Framework

5 GLOBAL COLLAGEN AND GELATIN MARKET FOR REGENERATIVE MEDICINE MARKET, BY SOURCE

• 5.1 Collagen Sources
  • 5.1.1 Bovine
  • 5.1.2 Porcine
  • 5.1.3 Marine
• 5.2 Gelatin Sources
  • 5.2.1 Bovine
  • 5.2.2 Porcine
  • 5.2.3 Others

6 GLOBAL COLLAGEN AND GELATIN MARKET FOR REGENERATIVE MEDICINE MARKET, BY APPLICATION

• 6.1 Collagen
  • 6.1.1 Orthopedic
  • 6.1.2 Wound Care
  • 6.1.3 Cardiovascular
  • 6.1.4 Others
• 6.2 Gelatin
  • 6.2.1 Wound Care
  • 6.2.2 Orthopedic
  • 6.2.3 Cardiovascular
  • 6.2.4 Others

7 GLOBAL COLLAGEN AND GELATIN MARKET FOR REGENERATIVE MEDICINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East And Africa

8 GLOBAL COLLAGEN AND GELATIN MARKET FOR REGENERATIVE MEDICINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Share
• 8.3 Vendor Landscape
• 8.4 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Integra Lifesciences Holdings Corporation
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Collagen Matrix, Inc.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Collagen Solutions PLC
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Royal DSM
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 VorniaBiomaterials Ltd.
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Symatese
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Nucollagen LLC.
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Gelita AG
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Nitta Gelatin Inc.
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 PB Gelatin
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research